In collaboration with Bonac Co., the team of Masahiko KURODA at Tokyo University of Medicine has developed a single-stranded RNA (“miR-29b Psh-match) that has a unique structure to avoid problems associated with the therapeutic uses of miRNAs. A comparison of miR-29b Psh-match and double-stranded miR-29b mimic indicated that the single-stranded form was significantly more effective towards fibrosis according to both in vivo and in vitro experiments in mice.
Nikkei Biotech news release, February 28, 2017
Bonac and Tokyo University of Medicine develop improved nucleic acid replacement therapy for pulmonary fibrosis